Eli Lilly And Co’s (NYSE:LLY) shares are trading higher with a session volume of 1.683 million versus an average volume of 3.12 million, according to data from Benzinga Pro. However, there is no news to justify the movement.
Investors eagerly await fourth-quarter 2023 results and guidance scheduled to be announced on February 6, with all eyes on the company’s blockbuster weight-loss drug Zepbound (tirzepatide).
The recently FDA-approved medication, introduced in November, has quickly triggered intense competition within the anti-obesity market.
This suggests the possibility of significant changes or disruptions